IDEAYA Biosciences (IDYA) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for IDEAYA Biosciences (NASDAQ: IDYA):

• 2/18/2026 – IDEAYA Biosciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 2/18/2026 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $49.00 price target on the stock.
• 2/18/2026 – IDEAYA Biosciences had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $50.00 price target on the stock.
• 2/18/2026 – IDEAYA Biosciences had its price target raised by analysts at Wedbush from $49.00 to $52.00. They now have an “outperform” rating on the stock.
• 1/22/2026 – IDEAYA Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/21/2026 – IDEAYA Biosciences had its price target raised by analysts at Royal Bank Of Canada from $41.00 to $45.00. They now have an “outperform” rating on the stock.
• 1/7/2026 – IDEAYA Biosciences is now covered by analysts at UBS Group AG. They set a “buy” rating and a $50.00 price target on the stock.
• 1/6/2026 – IDEAYA Biosciences had its price target raised by analysts at Truist Financial Corporation from $59.00 to $60.00. They now have a “buy” rating on the stock.

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.